FGFR2 and cholangiocarcinoma: Other FGFR inhibitors, such as BGJ398, showed an objective response rate of 14.8% (18.8% FGFR2 fusions only) and disease control rate of 75.4% (83.3% FGFR2 fusions only) in patients with FGFR-altered advanced cholangiocarcinoma [21].